What did the board approve?

The board approved the standalone audited financial results for the quarter and full year ended March 31, 2026.

What was the auditor's conclusion?

The auditors issued an unmodified opinion, meaning they found no material misstatements or qualifications in the financial statements.

Is there any new strategic information in the filing?

No. The filing is a standard earnings release with no unexpected announcements, guidance, or material surprises beyond the scheduled reporting.

Why is the market cap relevant context?

At ₹33 crore, Centenial Surgical Suture is a nano-cap company. Such stocks often have low liquidity and limited analyst coverage, making routine filings like this the primary source of public information.

Earnings · Medical Equipment · Micro cap

Centenial Surgical Suture posts FY26 results, auditors sign off clean

A routine annual filing for a nano-cap company. The auditors gave an unmodified opinion, but the results carry no strategic surprises.

— 1 earlier story on Centenial Surgical Suture Ltd. →

CSURGSU By Tipsheet Editorial 30 May 2026 · 9:28 PM IST Verify on BSE · NSE

Mkt cap₹26.71 cr

ROE0.00%

Debt / eq.0.40

₹33 cr Market capitalisation of Centenial Surgical Suture.

What's new

Board approved standalone audited results for Q4 and FY26, ending March 31, 2026.
Auditors issued an unmodified (clean) opinion on the financial statements.
Filing contains no guidance changes, strategic announcements, or material surprises.

Why this matters

This is a compliance filing for a nano-cap. The clean audit opinion is a baseline requirement for continued listing. The absence of new information means the event is already priced in and unlikely to move the stock.

What we're watching

Any subsequent management commentary or investor presentations.
The stock's liquidity profile given the ₹33 cr market cap.
Whether the next quarter's results show any change in profitability trend.

The full read

Centenial Surgical Suture, a ₹33 crore market-cap company, filed its annual results for the year ended March 31, 2026. The board signed off on the standalone audited accounts, and the auditors gave a clean, unmodified opinion. That's it. There is no new strategy, no guidance update, no surprise. For a nano-cap, this is the baseline. The filing meets its regulatory obligation and adds no new information for investors to act on.

Questions answered

What did the board approve?: The board approved the standalone audited financial results for the quarter and full year ended March 31, 2026.
What was the auditor's conclusion?: The auditors issued an unmodified opinion, meaning they found no material misstatements or qualifications in the financial statements.
Is there any new strategic information in the filing?: No. The filing is a standard earnings release with no unexpected announcements, guidance, or material surprises beyond the scheduled reporting.
Why is the market cap relevant context?: At ₹33 crore, Centenial Surgical Suture is a nano-cap company. Such stocks often have low liquidity and limited analyst coverage, making routine filings like this the primary source of public information.

Mentioned: Centenial Surgical Suture Ltd. · March 31, 2026 · Unmodified audit opinion

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Centenial Surgical Suture Ltd.

Pharmaceuticals

₹28 cr

Latest quarter · Mar 2026

Sales₹13 cr

Net profit−₹2 cr

Op. margin+7.4%

EPS−₹6.34

Strength & growth

Debt / equity0.40×

Current ratio1.98×

Sales CAGR+0.5%

Story so far

All notes on CSURGSU →

30 May 2026 · 9:28 PM IST Centenial Surgical Suture posts FY26 results, auditors sign off clean
41d ago Centenial Surgical Suture posts a ₹2.2 cr annual loss on flat revenue